These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 9164897)
1. Effect of sustained-release Verapamil on the morning systemic arterial pressure surge during daily activity in patients with systemic hypertension. Rosito GA; Gebara OC; McKenna CA; Solomon HS; Muller JE; Tofler GH Am J Cardiol; 1997 May; 79(9):1252-5. PubMed ID: 9164897 [TBL] [Abstract][Full Text] [Related]
2. Comparison of effects of controlled onset extended release verapamil at bedtime and nifedipine gastrointestinal therapeutic system on arising on early morning blood pressure, heart rate, and the heart rate-blood pressure product. White WB; Black HR; Weber MA; Elliott WJ; Bryzinski B; Fakouhi TD Am J Cardiol; 1998 Feb; 81(4):424-31. PubMed ID: 9485131 [TBL] [Abstract][Full Text] [Related]
3. A comparative trial of controlled-onset, extended-release verapamil, enalapril, and losartan on blood pressure and heart rate changes. Bakris G; Sica D; Ram V; Fagan T; Vaitkus PT; Anders RJ Am J Hypertens; 2002 Jan; 15(1 Pt 1):53-7. PubMed ID: 11824861 [TBL] [Abstract][Full Text] [Related]
4. Preventing increases in early-morning blood pressure, heart rate, and the rate-pressure product with controlled onset extended release verapamil at bedtime versus enalapril, losartan, and placebo on arising. White WB; Sica DA; Calhoun D; Mansoor GA; Anders RJ Am Heart J; 2002 Oct; 144(4):657-65. PubMed ID: 12360162 [TBL] [Abstract][Full Text] [Related]
5. Novel delivery system for verapamil designed to achieve maximal blood pressure control during the early morning. Neutel JM; Alderman M; Anders RJ; Weber MA Am Heart J; 1996 Dec; 132(6):1202-6. PubMed ID: 8969572 [TBL] [Abstract][Full Text] [Related]
6. Assessment of 'once daily' verapamil for the treatment of hypertension using ambulatory, intra-arterial blood pressure recording. Caruana M; Heber M; Brigden G; Raftery EB Eur J Clin Pharmacol; 1987; 32(6):549-53. PubMed ID: 3653223 [TBL] [Abstract][Full Text] [Related]
8. Differential effects of morning and evening dosing of nisoldipine ER on circadian blood pressure and heart rate. White WB; Mansoor GA; Pickering TG; Vidt DG; Hutchinson HG; Johnson RB; Noveck R Am J Hypertens; 1999 Aug; 12(8 Pt 1):806-14. PubMed ID: 10480474 [TBL] [Abstract][Full Text] [Related]
9. Verapamil and 24-hour ambulatory blood pressure monitoring in essential hypertension. Zachariah PK; Sheps SG; Schirger A; Spiekerman RE; O'Brien PC; Simpson KK Am J Cardiol; 1986 Feb; 57(7):74D-79D. PubMed ID: 3953429 [TBL] [Abstract][Full Text] [Related]
10. Treatment of mild hypertension with low once-daily doses of a sustained-release capsule formulation of verapamil. Davis PJ; Fagan TC; Topmiller MJ; Levine JH; Ferdinand KC J Clin Pharmacol; 1995 Jan; 35(1):52-8. PubMed ID: 7751413 [TBL] [Abstract][Full Text] [Related]
11. The efficacy and duration of action of sustained-release verapamil in essential hypertension. McCormack PM; Latham AN; Mee F; Atkins N; O'Brien ET; O'Malley K J Cardiovasc Pharmacol; 1989; 13 Suppl 4():S34-7. PubMed ID: 2475682 [TBL] [Abstract][Full Text] [Related]
12. Long-term safety and efficacy comparison of immediate-release and sustained-release oral verapamil in systemic hypertension. Frishman WH; Eisen G; Charlap S; Strom JA J Clin Hypertens; 1987 Dec; 3(4):605-9. PubMed ID: 3134517 [TBL] [Abstract][Full Text] [Related]
14. Effects of the chronotherapeutic delivery of verapamil on circadian blood pressure in African-American patients with hypertension. White WB; Johnson MF; Black HR; Fakouhi TD Ethn Dis; 1999; 9(3):341-9. PubMed ID: 10600056 [TBL] [Abstract][Full Text] [Related]
15. Gender and age effects on the ambulatory blood pressure and heart rate responses to antihypertensive therapy. White WB; Johnson MF; Black HR; Elliott WJ; Sica DA Am J Hypertens; 2001 Dec; 14(12):1239-47. PubMed ID: 11775133 [TBL] [Abstract][Full Text] [Related]
16. Noninvasive blood pressure monitoring evaluation of verapamil slow-release 240-mg antihypertensive effectiveness. Novo S; Alaimo G; Abrignani MG; Longo B; Muratore G; Strano A J Cardiovasc Pharmacol; 1989; 13 Suppl 4():S38-41. PubMed ID: 2475683 [TBL] [Abstract][Full Text] [Related]
17. Treatment of mild to moderate hypertension with verapamil slow-release in outpatients. Collaborative Group of the Spanish League for the Fight Against Hypertension. Gómez Pajuelo C; Pérez Naranjo J; Ruiz Martínez I J Cardiovasc Pharmacol; 1989; 13 Suppl 4():S50-2. PubMed ID: 2475687 [TBL] [Abstract][Full Text] [Related]
18. Verapamil 240 SR versus verapamil 120 SR in arterial hypertension. A randomized double-blind, placebo-controlled study with 24-hour ambulatory blood pressure monitoring. Corea L; Bentivoglio M; Berioli S; Bianchini C; Savino K; Sardina M Cardiovasc Drugs Ther; 1990 Dec; 4(6):1501-7. PubMed ID: 2081142 [TBL] [Abstract][Full Text] [Related]
19. Comparison of sustained-release formulations of nicardipine and verapamil for mild to moderate systemic hypertension. Gradman AH; Frishman WH; Kaihlanen PM; Wong SC; Friday KJ Am J Cardiol; 1992 Dec; 70(20):1571-5. PubMed ID: 1466325 [TBL] [Abstract][Full Text] [Related]
20. Nocturnal dosing of a novel delivery system of verapamil for systemic hypertension. Verapamil Study Group. White WB; Anders RJ; MacIntyre JM; Black HR; Sica DA Am J Cardiol; 1995 Aug; 76(5):375-80. PubMed ID: 7639163 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]